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Abstract 
Cisplatin is a widely used chemotherapeutic agent for treatment of various cancers. However, treatment with cisplatin 
is associated with drug resistance and several adverse side effects such as nephrotoxicity, reduced immunity towards 
infections and hearing loss. A Combination of cisplatin with other drugs is an approach to overcome drug resistance 
and reduce toxicity. The combination therapy also results in increased sensitivity of cisplatin towards cancer cells. The 
mitogen activated protein kinase (MAPK) pathway in the cell, consisting of extracellular signal regulated kinase, c‑Jun 
N‑terminal kinase, p38 kinases, and downstream mediator p90 ribosomal s6 kinase (RSK); is responsible for the regula‑
tion of various cellular events including cell survival, cell proliferation, cell cycle progression, cell migration and protein 
translation. This review article demonstrates the role of MAPK pathway in cisplatin based therapy, illustrates different 
combination therapy involving cisplatin and also shows the importance of targeting MAPK family, particularly RSK, to 
achieve increased anticancer effect and overcome drug resistance when combined with cisplatin.
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Background
Cisplatin has been widely used since its approval in 1978 
against a wide spectrum of tumors including lung, ovar-
ian, testicular, bladder, colorectal and head and neck can-
cers [1, 2]. Although cisplatin is a widely used drug for 
cancer chemotherapy, it is also associated with severe 
dose limiting side effects, and acquired or intrinsic tumor 
resistance. To circumvent this hindrance, cisplatin has 
been combined with agents that potentiate the activity of 
cisplatin towards tumor cells with less toxic side effects 
[3–6]. The MAPK pathway, including ERK, JNK and p38 
kinase, plays a pivotal role in cell survival, proliferation 
and migration of tumor cells [7–9]. However, target-
ing these signaling pathways remains controversial as 
inhibition of this pathway either contributes or prevents 
cisplatin induced apoptosis. The RSK is a protein which 
acts as a downstream mediator of MAPK–ERK signaling 
pathway, and is also associated with cell survival, prolif-
eration, cell cycle progression and migration [10–13]. 
Although a previous study has shown that RSK inhibition 
resulted in decreased cell migration and proliferation of 
cancer cells [14], the effect of combination therapy of 
cisplatin with RSK inhibition is not clearly understood. 
Therefore, the aim of this review is to discuss the role of 
MAPK pathway in cisplatin based chemotherapy and to 
elucidate the possibilities of combination of RSK inhibi-
tion along with cisplatin in order to increase the antican-
cer effect and reduce resistance and toxic side effects of 
cisplatin.
Main text
Cisplatin
Cisplatin is the first platinum drug approved globally 
and has been used as a drug for cancer chemotherapy for 
more than 30  years [1]. Cytostatic property of cisplatin 
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was discovered by Barnett Rosenberg in the late 1960s 
when he observed anti-proliferative effect of platinum 
electrodes on bacterial suspension. Cisplatin has gained 
clinical success and has been proven to target various 
kinds of cancers, namely, lung, head and neck, bladder, 
cervical, and ovarian cancers [2].
Upon cisplatin entry to the cell, it becomes activated 
by hydrolysis. Chloride ions are displaced by water mole-
cules resulting in a strong positive electrophile that cova-
lently binds to any nucleophile such as nitrogen in purine 
residues. The most reported reaction is the 1,2-intras-
trand cross-linkage of the activated cisplatin with the 
purine residues at nitrogen (N7) which was demon-
strated in vitro in DNA of cisplatin-treated salmon sperm 
cells. These results were further approved in another 
in  vivo experiment that analyzed white blood cells of 
cancer patients [15, 16]. Cisplatin causes damage in the 
DNA leading to p53 (tumor suppressor gene) activation. 
Meanwhile, damaged DNA is subjected to repair via p21 
mediated cell cycle arrest. When the damaged DNA is 
not repairable, p53 induces apoptosis by inhibition of 
Bcl2 and consequent caspase activation [17]. The main 
mechanism of cisplatin-induced cancer cell death is via 
apoptosis. Apoptosis is a procedure of programmed cell 
death, and is generally manifested by distinct morpho-
logical changes to the cell, e.g. cell shrinkage, chromatin 
condensation, plasma membrane “budding”, exposure 
of phosphatidyl serine at the cell surface, and caspase 
activation [18]. The stimulation of a family of cysteines, 
otherwise known as caspases, is a critical step during 
the beginning stages of apoptosis. Caspases are charac-
terized as either initiators or executioners of this cell 
death mechanism. The activation of caspases is depend-
ent upon several stimuli, e.g. caspase-8 (initiator), acti-
vated by plasma membrane death receptors (DR), and 
caspase-9 (initiator), associated with mitochondrial col-
lapse, resulting in caspase-3 and -7 (executioners) activa-
tion [19]. Executioner caspases are responsible for many 
of the biochemical activities contributing towards the 
induction of apoptosis. This includes poly (ADP-ribose) 
polymerase (PARP) cleavage and activation, which leads 
to DNA fragmentation. Apoptosis is carried out by 
two major pathways known as the extrinsic and intrin-
sic pathways [20]. The extrinsic pathway begins when 
ligands bind to tumor necrosis factor-α (TNFα) recep-
tor family leading to the enrollment of procaspase-8 
by adaptor molecules, resulting in the development of 
death-inducing signaling complex (DISC) [21]. However, 
the intrinsic pathway commences when the cell undergo 
stress such as DNA damage, which subsequently leads to 
mitochondrial cytochrome c release and interaction with 
activating factor-1 (APAF-1), to form an active apopto-
some structure, which thereby activates procaspase 9. In 
response, and in order to regulate DNA damage induced 
by apoptosis, Bcl-2 family proteins are regulated and 
undergo several modulations via controlling the release 
of cytochrome c. Therefore, genotoxic stress induced 
by cisplatin can result in the activation of several signal 
transduction pathways, contributing towards the induc-
tion of apoptosis.
Strategies to overcome cisplatin resistance and toxicity
Although cisplatin is widely used anticancer drug, sig-
nificant challenges still remain in regards to cisplatin 
resistance and cisplatin induced toxicity. There are differ-
ent mechanisms attributed towards tumor resistance to 
cisplatin.
Cisplatin is introduced into cells either through pas-
sive diffusion or via transporters (copper transporter, 
CTR1) [3]. Previous studies have reported that loss of 
CTR1 resulted in less platinum entering cells and, con-
sequently, drug resistance [22, 23]. Another reason for 
cisplatin resistance is due to the inactivation of active 
cisplatin by glutathione or metallothionein present in 
the cytoplasm of cells. These species are rich in sulphur 
containing amino acids like cysteine and methionine and 
leads to inactivation of platinum by binding to sulphur. 
Active efflux of platinum from the cells through copper 
exporters (ATP7A and ATP7B) and excretion through 
glutathione S-conjugate export GS-X pump, also contrib-
ute towards cisplatin resistance. Increased DNA repair 
mechanisms and downregulation of apoptotic pathways 
are other factors mediating cisplatin resistance [3].
Treatment with cisplatin has been associated with sev-
eral toxic side effects including nephrotoxicity, oxidative 
damage to liver, cardiomyopathy, allergic reactions, oto-
toxicity and gastrotoxicity [15, 24–26].
Cisplatin resistance to tumor cells can be overcome 
by adopting techniques (Fig.  1) to improve the delivery 
of cisplatin to the target DNA. This can be achieved by 
administering cisplatin in polymers or liposomes, and by 
inhibiting levels of species (glutathione and metallothio-
nein) which inactivate cisplatin and thereby decrease its 
antitumor efficiency [3]. Recent in vitro and in vivo stud-
ies demonstrated that nanoscale micelles encapsulating 
ethacraplatin, a conjugate of cisplatin, and ethacrynic 
acid (inhibitor of glutathione S-transferase) resulted in 
enhanced accumulation of active cisplatin in cancer cells 
by inhibiting glutathion S transferase and circumvent-
ing deactivation of cisplatin [27]. Cisplatin resistance can 
also be controlled by using antisense oligodeoxynucleo-
tides (ODN) targeting responsible oncogenes for cispl-
atin resistance, where the ODN hybridize with the target 
mRNA and prevents its translation; or by inactivation of 
oncogenes by ribozymes which are RNAs with site spe-
cific ligation activity [28].
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Owing to treatment resistance and toxic side effects 
of cisplatin, implementation of combination therapy has 
gained much importance with regards to increased sen-
sitivity of cisplatin towards cancer cells when combined 
with other drugs. The combination of other drugs with 
cisplatin may result in increased anticancer effect, there 
by result in reducing the dose of cisplatin and ultimately 
reduce toxic side effects. Hence, combination therapy 
may be adopted to evade cisplatin toxicity and resistance 
to cancer cells.
Combination therapy to overcome resistance and toxicity
Cisplatin with chemotherapeutic agents
To overcome the occurrence of resistance observed in 
patients relapsing from cisplatin treatment, cisplatin is 
commonly used in combination with various chemother-
apeutic drugs and is the basis of many cancer treatments 
[15]. Cisplatin has been used with a wide range of other 
cancer drugs for the treatment of ovarian [29], lung [30], 
breast [31, 32], liver [33], colon [34], prostate [34] and 
cervical [35] cancers, among many others [15].
Paclitaxel, a pro-apoptotic and mitotic agent, is used 
to treat numerous cancers including ovarian, lung and 
breast [15]. Paclitaxel has been shown in combination 
with 5-fluorouracil and cisplatin for the treatment of 
advanced gastric carcinoma, and displayed tolerable 
toxicity in patients [36]. A 2017 phase I trial [37] has 
also demonstrated that the combination of cisplatin and 
paclitaxel with triapine, a ribonucleotide reductase inhib-
itor, can be safely administered together in patients with 
metastatic or advanced stage solid tumor cancers.
The combination of doxorubicin and cisplatin has been 
demonstrated to be effective and well tolerated in cancer 
patients [15]. In  vitro anti-tumor studies investigating 
synergistic cisplatin + doxorubicin combination treat-
ment have been carried out with the aim of overcoming 
multi-drug resistance [38]. With the use of polymeric 
nanogels targeting delivery, the combination was effec-
tive for the multidrug-resistant MCF-7/ADR tumor and 
displayed minimal side effects.
In aims to enhance the cytotoxic effects of interferon, 
a group of natural cytokines displaying antineoplastic 
effects, specifically in advanced hepatocellular carcinoma 
[39], interferon was used in combination with other ther-
apeutic agents, including 5-fluorouracil, doxorubicin and 
cisplatin [40]. The modified combination was associated 
with an improved response and overall survival in hepa-
tocellular carcinoma patients.
Cisplatin and capecitabine in combination have been 
demonstrated in gastrointestinal cancers and have shown 
promising results [41, 42]. However, there remains to be 
limited data on capecitabine in metastatic breast can-
cers. A study carried out by Lee et al. [41], demonstrated 
capecitabine and cisplatin in combination in anthracy-
cline and taxane resistant, heavily pre-treated HER2 neg-
ative metastatic breast cancer, displayed clinical benefit 
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Fig. 1 Various strategies to overcome cisplatin resistance. Delivery of cisplatin to target DNA can be improved by administering cisplatin in 
liposomes or polymers, and by inhibiting cisplatin inactivating species like glutathione and metallothionein. Cisplatin resistance can also be con‑
trolled by using antisense oligodeoxynucleotides (ODN) targeting responsible oncogenes for cisplatin resistance or by enhancement of cisplatin 
activity by combining with other drugs
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with tolerable toxicity in patients. These findings sug-
gest that the proposed combination may offer an option 
for patients displaying cancer progression after anthra-
cycline and taxane treatment introduction and also 
showed promise for HR positive metastatic breast cancer 
patients. Therefore, combination of cisplatin with other 
chemotherapeutic agents has resulted in increased effec-
tiveness of therapy with reduced side effects.
Cisplatin with natural products
Many recent studies reported that combination therapy 
using natural products, in particular Chinese herbal 
medicines, is a beneficial therapeutic strategy to over-
come the side effects and drug resistance of cisplatin 
[43–46]. Natural compounds like curcumin improved 
the efficacy of cisplatin by increasing the sensitivity and 
inhibition of metastasis by mediating through p21 and 
cyclin D1 in non-small cell lung cancer cell lines A549 
and H2170 [5]. In a study which included an extract of 
roots of a Chinese herb, Sun Bai Pai, showed apoptosis 
induction and autophagy by the herbal extract in A549 
cells. This effect showed a synergistic action when cis-
platin was treated to the autophagic cells indicating that 
Sun Bai Pai extract improved the cancer cell killing effi-
ciency of chemotherapy drugs even at reduced doses 
[45]. It suggests that toxic side effects of cisplatin can 
be reduced in combination therapy. Another example 
of combination therapy is with melatonin which is an 
indolamine molecule produced by pineal gland and other 
organs. Its main function is to control circadian rhythms 
and to treat insomnia. Melatonin enhanced the cisplatin 
induced cytotoxicity and apoptosis in SK-LU-1 lung can-
cer cells as demonstrated by an increase in S-phase arrest 
[47]. Moreover, combined treatment of melatonin and 
cisplatin synergistically inhibited the viability of SK-OV-3 
ovarian cancer cells. Co-treatment of cisplatin with mela-
tonin increased sub G1 DNA content and TUNEL posi-
tive cells compared to cisplatin control, suggesting that 
melatonin augments the cisplatin induced apoptosis in 
SK-OV-3 ovarian cancer cells which is consistent to the 
cleavage of caspase 3 and poly-(ADP-ribose) polymer-
ase (PARP) in the combination treatment. This syner-
gism between cisplatin and melatonin was achieved by 
inactivation of extracellular signal regulated kinase/p90 
ribosomal s6 kinase/heat shock protein 27 cascade in 
SK-OV-3 cells [44]. Therefore, combination therapy of 
cisplatin with natural products not only reduced the toxic 
side effects of cisplatin but also augmented the anticancer 
activity of cisplatin.
Cisplatin with targeted therapeutic agents
Through the advancements made in our knowledge of 
tumor biology, the vital role of targeted therapies as 
either first or second line treatment regimens for can-
cer has been established. The plethora of data accumu-
lated, especially over the last few years, has suggested the 
promising potential of targeted therapeutic agents use in 
combination to enhance and support the anti-tumoral 
effects of conventional chemotherapies [48–50].
Such studies include combination therapy of cispl-
atin with C-75, which is a selective inhibitor of Fatty 
Acid Synthase (FASN) [51]. FASN is an enzyme that 
facilitates de novo synthesis of fatty acids. FASN is over-
expressed in various cancers, including epithelial ovar-
ian carcinoma (EOC). This study showed that C-75 in 
combination with cisplatin caused growth inhibition of 
EOC tumors in nude mice via FASN down-regulation 
and caspase activation. Moreover, treatment of EOC 
cells with C-75 augmented the effect of cisplatin medi-
ated stimulation of apoptosis. Such findings suggest 
that FASN could potentially be a therapeutic target in 
this type of cancer, either alone or in combination with 
chemotherapeutic compounds, including cisplatin to 
produce synergistic effect [51]. Another example of syn-
ergistic effect is demonstrated when cisplatin is com-
bined with PHA665752 [52], a c-Met inhibitor, which 
resulted in augmented apoptosis of EOC cells. A syner-
gistic inhibition of EOC was also observed in xenograft 
tumor growth in a nude mouse model, identifying the 
role of hepatocyte growth factor (HGF)/c-Met pathways 
in mediating anti-apoptotic signals via AKT in EOC. 
Furthermore, it has been shown that co-treatment of 
EOC cells with cisplatin and bortezomib produced 
more pronounced effect on cell proliferation, apoptosis 
and S-phase kinase protein 2 (SKP2) down-regulation 
causing accumulation of p27kip1which is a cyclin-
dependent kinase inhibitor [53]. Gleevec (Imatinib) is 
a FDA approved drug for chronic myelogenous leuke-
mia, where the activity of tyrosine kinase is inhibited 
by Gleevec by binding to the receptor. Gleevec was also 
investigated to show its potential activity against cispl-
atin resistant A549 lung cancer cells. The co-treatment 
of cisplatin and Gleevec resulted in synergistic cytotox-
icity against A549 cells [6] suggesting that combination 
therapy with Gleevec reduced the resistance of cisplatin 
against cancer cells. Sorafenib is an approved multiki-
nase inhibitor for the treatment of osteosarcoma. It was 
found that combination of sorafenib and cisplatin in 
reduced concentrations considerably reduced the cell 
proliferation, migration, invasion and colony formation. 
Furthermore this combination treatment induced cell 
apoptosis and arrest in the G0/G1 stage of cell cycle in 
human Saos-2 osteosarcoma cells. The combination also 
reduced the tumor growth in nude mouse model when 
compared to individual drug alone suggesting a syner-
gistic growth inhibition [54]. These findings suggest that 
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targeting various cancer promoting pathways along with 
cisplatin treatment helped to reduce the dose of cispl-
atin to produce increased anticancer effect. Moreover, 
reducing the dose of cisplatin diminished the toxic side 
effects of cisplatin.
Cisplatin and inactivation of specific genes
A recent study demonstrated that silencing of YB-1 pro-
tein, expressed in various forms of malignant tumors, 
sensitized SH-SY5Y neuroblastoma cells to cisplatin and 
stimulated cisplatin induced apoptosis by down regulat-
ing multidrug resistance (MDR)1 protein through NFkB 
signaling pathway [55].
Inactivation of oncogenes responsible for cisplatin 
resistance is indeed a strategy to improve sensitivity of 
cisplatin towards tumor cells. In  vitro approaches using 
antisense oligo deoxy nucleotides and by ribozymes 
(RNAs that have the ability of ligation at particular sites) 
successfully led to the inactivation of target genes like c-
fos, c-jun, bcl-2, c-myc, H-ras etc. resulting in improved 
activity of cisplatin against cancer cells [28].
An example of combination therapy includes delta-
tocotrienol with cisplatin where the combination resulted 
in downregulation of Notch-1 via inhibition of NFkB 
signaling pathways resulting in controlling non-small cell 
lung cancer, while reducing the effective dose of cisplatin 
[56] suggesting that effective treatment can be achieved 
with reduced side effects and toxicity of cisplatin.
Cisplatin and inhibition of survival pathways
Major survival pathways and their aberrant activa-
tion have been reported to frequently occur and con-
tribute towards the development and progression of 
tumor growth, including the PI3K (phosphatidylinositol 
3-kinase)/AKT (protein kinase B)/mTOR (mammalian 
target of rapamycin) signaling pathway [57–59]. Numer-
ous studies have hence been carried out investigating the 
interaction between PI3K or mTOR inhibitors and cispl-
atin, which in fact have displayed a synergistic anti-tumor 
effect in chemo-naive or resistant cancers, e.g. mela-
noma, breast, lung and nasopharyngeal cancers [60–63].
Previous studies explored the in vitro effects of mTOR 
inactivation and evaluated the using of Torin2, an mTOR 
inhibitor, in EOC cell lines. Sub toxic doses of Torin2 
potentiated cisplatin-induced apoptotic activity in EOC. 
In  vivo studies also revealed that in combination of 
Torin2 and cisplatin, tumor growth in nude mice was 
synergistically inhibited. Overall, such studies highlight 
the importance and potential of targeting the mTOR sur-
vival pathway, suggesting that co-treatment of cisplatin 
and mTOR inhibitors, such as Torin2, may be beneficial 
for the management of EOC and various other resistant 
cancers [64].
Previous studies have demonstrated that Akt inhibi-
tor, MK-2206, sensitizes cisplatin towards gastric cancer 
cell line AGS. MTT assay and apoptosis assay demon-
strated that cisplatin followed by MK-2206 resulted in 
synergistic effect of proliferative inhibition and apoptosis 
respectively for the combination treatment when com-
pared to the monotherapy. The combination treatment 
also resulted in cleavage of PARP contributing to apop-
tosis [4]. The Akt inhibitor, MK-2206, also enhanced the 
cytotoxicity of cisplatin in SK-OV-3 ovarian cancer cells, 
where consecutive treatment of cisplatin followed by 
MK-2206 resulted in synergistic inhibition of cell pro-
liferation, enhancement of intracellular reactive oxygen 
species, and downregulation of pro-survival protein, 
Bcl-2 [65].
Cisplatin and mitogen activated protein kinases (MAPKs)
MAPKs are a highly conserved family of structurally 
related serine/threonine protein kinases responsible for 
coordinating a variety of extracellular signaling pathways, 
regulating fundamental cellular processes involved in cell 
growth and survival [7, 9, 66]. There are three subfamilies 
in MAPK family, including ERK (member of Ras/MAPK), 
JNK and p38 kinases [10, 67, 68].
Although previous findings have identified cisplatin 
to result in ERK activation in several forms of cancer, 
whether this activation prevents or contributes to cispl-
atin-induced apoptotic effects remains greatly controver-
sial [69–75]. Cisplatin-induced ERK activation precedes 
p53-mediated DNA damage response as ERK directly 
phosphorylates p53, resulting in upregulated expression 
of p21, 45kd-growth arrest and DNA damage (GADD45), 
and mouse double minute 2 homolog (Mdm2) [76]. 
As such, ERK activation may result in cell cycle arrest 
thereby supporting repair of DNA damage induced by 
cisplatin, via the tumor suppressor p53 (Fig. 2). Further-
more, p53 also directly affects the expression of down-
stream genes that regulates the sensitivity to apoptosis, 
activating transcription of Bax (promotes apoptosis) and 
repressing transcription of Bcl-2 (inhibits apoptosis) [28].
Furthermore, DNA damage results in the activation 
of JNK. The activation of JNK pathway results via both 
the cis and trans forms of cisplatin. DNA damage conse-
quently leads to the stabilization and activation of p73, 
a pro-apoptotic protein related to p53, forming a com-
plex with JNK, mediating apoptosis (Fig.  2) induced by 
cisplatin [77]. In addition, various other stress stimuli 
such as environmental stress are important mediators 
of apoptosis induced via cisplatin. This has been found 
to occur through the activation of p38 MAPK family. It 
was reported that cisplatin induces EGFR internaliza-
tion mediated by p38 MAPK dependent phosphoryla-
tion of receptor [78]. Cisplatin induces stabilization of 
Page 6 of 12Achkar et al. J Transl Med  (2018) 16:96 
p18 (Hamlet), a protein regulated by p38 MAPK. This 
enhanced the ability of p53 to interact with and activate 
PUMA and NOXA, critical pro-apoptotic genes (Fig. 2). 
Therefore, p38 MAPK pathway plays a crucial part in 
the regulation of cisplatin ability to induce apoptosis 
[79]. Moreover, sustained activation of JNK/p38 MAPK 
pathways by cisplatin has resulted in inducing apop-
tosis in ovarian carcinoma cells [80]. Previous studies 
also showed that inhibition of either JNK or p38 kinase 
attenuated cisplatin induced apoptosis in cervical can-
cer cells, supporting the role of JNK and p38 in cisplatin 
response [81]. In contrast, foregoing study has reported 
that inhibition of p38 MAPK pathway resulted in upregu-
lation of reactive oxygen species, mediating activation of 
JNK and thereby sensitizing human tumor cells to cispl-
atin induced apoptosis [82]. In addition, the same study 
has reported the use of mouse model for breast cancer to 
confirm that inhibition of p38 MAPK conjoins with cispl-
atin therapy to decrease tumor size and malignancy [82]. 
This is also in accordance with another study where p38 
MAPK inhibition potentiates cisplatin induced apoptosis 
via glutathione depletion and drug transport alteration in 
epithelial renal tubule cell lines [83].
The MAPK cascade also includes upstream signal 
transducing molecules MEK (MAPK ERK kinase), Raf 
and Ras. Recent studies have reported the combination 
of MEK inhibitors along with cisplatin in in  vitro and 
clinical trials [84, 85]. MEK inhibitor along with cispl-
atin resulted in enhanced apoptotic response in platinum 
sensitive ovarian carcinoma cells. Phase I/II clinical tri-
als in biliary cancer patients observed significant activ-
ity of MEK inhibitor in combination with cisplatin in 
selected patients with prolonged and complete response 
to treatment.
p53
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p73JNK
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Fig. 2 Illustration of MAPK pathway and the role of cisplatin in promoting apoptosis or cell survival. Cisplatin‑induced ERK activation phosphoryl‑
ates p53 which in turn upregulates expression of p21, 45kd‑growth arrest and DNA damage (GADD45), and mouse double minute 2 homolog 
(Mdm2) thereby promoting cell cycle arrest and supporting repair of DNA damage induced by cisplatin. ERK also activates its downstream media‑
tor, RSK which promotes cell survival and metastasis. Cisplatin induced DNA damage activates JNK and p73 and promotes their complex formation 
and leads to apoptosis. Cisplatin induces stabilization of p18 (Hamlet), a protein regulated by p38 MAPK. This enhances the ability of p53 to interact 
with and activate pro‑apoptotic genes, PUMA and NOXA
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Cisplatin and p90 ribosomal s6 kinase (RSK)
The RSK proteins are the downstream mediators of the 
Ras–ERK signal transduction pathway. ERK-mediated 
phosphorylation/activation of RSK plays an important 
role in regulation of protein translation, cell cycle pro-
gression and migration [10, 12, 13]. In addition, RSK 
proteins have been shown to induce proliferation and 
survival of cells by enhancing the expression of anti-
apoptotic or pro-survival genes, and inhibiting pro-
apoptotic genes [11]. A recent research study reported 
that RSK plays a stimulatory role on ethanol induced 
hepatocellular carcinoma progression by activating anti-
apoptotic factor Bcl-2 and NHE1, known to regulate cell 
survival [86].
In humans, four RSK isoforms (RSK 1–4) and two 
structurally related homologs have been identified [87]. 
Although the RSK isoforms 1–3 are functional, there is a 
better understanding of RSK1 and RSK2, which display a 
higher similarity structurally, having a sequence identity 
of 73%. Furthermore, both isoforms have been associ-
ated with tumorigenesis in a wide range of human can-
cers [88]. More specifically, RSK1, reported to be more 
frequently activated in melanoma cancer cells, however, 
were found to be reduced in metastasized lung tissue 
compared to the primary tumor [8, 89]. Invasiveness and 
metastasis in head and neck squamous carcinoma cells 
has been shown to be promoted by RSK2. In addition, 
RSK2 has reported to contribute towards the survival 
of multiple myeloma cells [90, 91]. Breast and prostate 
cancer patients have also displayed higher expression of 
RSK1 and RSK2 compared to non-cancerous tissue [92, 
93]. However, the functions of RSK4 does not resemble 
to the Ras–ERK pathway. RSK4 has been shown to be 
involved in p53 mediated cell growth arrest and in onco-
gene stimulated cellular senescence. The overexpres-
sion of RSK4 decreased breast cancer cell proliferation 
and promoted G0/G1 phase cell cycle arrest. RSK4 has 
also been reported to be over expressed in greater than 
50% of primary malignant lung cancers. RSK3 and RSK4 
facilitate resistance to PI3 kinase inhibitors in breast can-
cer [87]. However, recent research has shown that RSK4 
is expressed at low levels in malignant ovarian tumors 
which correlate with advanced stages of the disease, and 
cisplatin increases the expression of RSK4 in SKOV3 and 
TOV112D ovarian cancer cell lines [94]. Therefore, the 
functions of RSK3 and RSK4 in cancer have not yet been 
clearly identified.
It is proposed that targeting anti-apoptotic signals 
associated with the promotion of cell survival may be a 
promising strategy to optimize the effectiveness of con-
ventional chemotherapeutic agents. RSK mediated sign-
aling involves the phosphorylation and inactivation of 
pro-apoptotic proteins and the activation of transcription 
factors and translational machinery that promote cell 
survival. RSK1 and RSK2 activate pro-survival proteins 
Bcl-2 and Bcl-xL by post translational phosphoryla-
tion and inactivation of the pro-apoptotic protein Bad, 
enhancing its ability to bind 14-3-3 proteins and pre-
venting its heterodimerization with the pro-survival 
proteins. RSK1 and RSK2 also phosphorylate CREB lead-
ing to increased transcription of Bcl-2 and promote cell 
survival. Also, RSK1 directly inhibits caspase activity, 
promoting cell survival. RSK phosphorylates and inhib-
its GSK3β to promote stabilization of cyclin D1 resulting 
in cell cycle progression and cell-survival [87]. Previous 
study has reported that inhibition of RSK with a dihy-
dropteridinone, BI-D1870, which is a potent RSK inhibi-
tor, decreases cell migration and proliferation of A549 
human lung adenocarcinoma cells, through phospho 
GSK 3β [14]. Other inhibitors of RSK include SL0101, 
LJH685, LJI308 and BIX 02565 which are ATP-competi-
tive inhibitors of the N-terminal kinase domain of RSK, 
and FMK which is a covalent inhibitor of the C-ter-
minal kinase domain of RSK [10]. Inhibition of RSK2 
(ser227) with BI-D1870 induced apoptosis mediated cell 
death resulting in regressed myeloma cell proliferation 
[95]. Moreover, combination of BI-D1870 with mTOR 
inhibitor (everolimus) or histone deacetylase inhibi-
tor (MS-275) or BH3-mimic inhibitor for BCL2/BCLXL 
(ABT-263), resulted in synergistic or additive anti-pro-
liferative effects in myeloma cells suggesting that RSK2 
(ser227) is a potential target in treating patients with 
multiple myeloma [95]. Furthermore, our own research 
has demonstrated the effect of combination treatment 
of BI-D1870 along with cisplatin on migration and apop-
tosis of A549 lung cancer cells. Our unpublished results 
indicate that BI-D1870 potentiates cisplatin induced 
apoptosis and inhibition of metastasis in non-small cell 
lung cancer. A recent study showed that inhibition of 
RSK with BI-D1870 overcame the drug resistance to 
inhibition of Sonic Hedgehog signaling pathway, which 
has been implicated in the pathogenesis of a variety of 
human cancers [87]. In a study on ovarian cancer cell 
line (A2780), treatment with cisplatin downregulated the 
expression of RSK2. Furthermore, silencing of RSK2 gave 
rise to improved cisplatin sensitivity [96]. These findings 
suggest that inhibition of RSK has the potential to sensi-
tize tumors to anticancer agents.
Conclusion
This review article depicted the importance of combina-
tion therapy in treatment of cancer. Standard chemother-
apy with cisplatin has limitations, such as drug resistance 
and its toxic side effects. However, these limitations can 
be overcome by administering low doses of cisplatin, 
which can be achieved in combination with such agents 
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which would increase the sensitivity of cisplatin towards 
cancer cells. Studies conducted in recent years suggested 
the importance of administering targeted therapeutic 
agents in combination with cisplatin to enhance the anti-
tumoral effects of cisplatin. It would be beneficial to tar-
get the major cell survival pathways that are upregulated 
in various types of cancers. The MAPK family, including 
its members ERK, p38, JNK and downstream mediator, 
RSK, executes major cellular functions like prolifera-
tion, survival and differentiation. However, the inhibition 
of ERK, p38 and JNK either prevents or contributes 
towards cisplatin induced apoptosis remains controver-
sial; which necessitates focusing on inhibition of RSKs 
which are the downstream effectors of the ERK/MAPK 
signaling cascade. RSKs are implicated in various cellular 
processes and modulate cell proliferation, tumorigenesis 
and metastasis in various cancers. Therefore, as shown 
in Fig. 3, cisplatin causes DNA damage resulting in p53 
activation leading to inhibition of pro-survival proteins 
and consequent caspase activation and apoptosis. On 
the other hand, inhibition of pro-apoptotic signals by 
RSK is controlled and limited by RSK inhibitors, there by 
promoting apoptosis. It is also worthy to note that RSK 
isoforms (RSK 1–4) in different tissues varies in their 
expression levels. RSK1 is expressed predominantly in 
the lung, kidney and pancreas [97]. RSK2 and RSK3 are 
highly expressed in heart, skeletal muscle and pancreas 
[97, 98]. RSK4 expression is much lower when compared 
with other RSKs. Previous study on mice demonstrated 
that RSK4 is expressed in brain, heart, kidney and skele-
tal muscle, whereas in lung, adipose tissue, liver and pan-
creas, RSK4 expression was not detected [97, 99]. This 
Fig. 3 Illustration of combination therapy of cisplatin and RSK inhibitors. Cisplatin causes DNA damage to cell resulting in p53 activation which in 
turn inhibits pro‑survival signals that regress caspase activation. Inhibition of RSK by cisplatin and RSK inhibitors result in inhibition of pro‑apoptotic 
signals there by increasing caspase activation leading to apoptosis. Combination therapy with cisplatin along with RSK inhibitors may result in bet‑
ter inhibition of cancer progression
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suggests that the effectiveness of RSK inhibitors used in 
combination therapy with cisplatin is also determined by 
the type of cancer based on tissues and organ.
Although this review focused on cisplatin, the find-
ings discussed here are not only specific to cisplatin but 
also applicable to a class of platinum derived chemo-
therapeutic drugs. Platinum derived agents like car-
boplatin and oxaliplatin are other globally approved 
anticancer drugs and have similar mechanism of action 
as cisplatin [1, 2]. Carboplatin is a second generation 
platinum drug which is used in combination with pacli-
taxel against ovarian cancer [2, 100]. In  vitro studies 
have proved synergistic effect of carboplatin in combina-
tion with cytosine arabinoside and mitoxantrone against 
human leukemia cell lines [101]. Previous studies have 
also demonstrated synergistic antitumor efficacy of car-
boplatin and trastuzumab in metastatic breast cancer 
[102]. A recent study has demonstrated that the HSP90 
inhibitor, ganetespib synergizes the antitumor efficacy 
of carboplatin in ovarian cancer cells in vitro and tumor 
xenografts in  vivo [103]. Moreover, a recent study has 
demonstrated that combination of carboplatin with 
either everolimus (mTOR inhibitor) or trametinib (ERK 
inhibitor) decreased cellular proliferation of astrocytoma 
cells [104]. Furthermore, everolimus sensitized astrocy-
toma cells to carboplatin treatment, despite astrocytoma 
cells being resistant to everolimus treatment alone. These 
findings together suggested that combination therapy 
increased the anticancer activity and overcame drug 
resistance. Other platinum derived drugs such as nedapl-
atin and lobaplatin have been used in combination ther-
apy in clinical trials of metastatic oesophageal carcinoma 
[1]. Heptaplatin is another platinum derived drug applied 
in clinical trials in combination therapy for head and 
neck cancer [1]. The newly developed platinum based 
drugs were to reduce the resistance and toxicity caused 
by cisplatin. Carboplatin was preferred as the platinum 
agent of choice over cisplatin in advanced ovarian can-
cer in palliative settings owing to its less nephrotoxic-
ity and neurotoxicity when compared to cisplatin [105]. 
However combination therapy based on carboplatin was 
found to be inferior to that based on cisplatin [105]. This 
suggests that cisplatin is still a drug of choice in combina-
tion therapy for cancer treatment.
In conclusion, targeting MAPK pathway predominantly 
in its downstream signaling cascade would be favorable 
in cancer treatment. A combination therapy of platinum 
based drugs with a RSK inhibitor would be a beneficial 
strategy to overcome the resistance and toxic side effects 
of platinum drugs and ultimately to combat cancer.
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